skip to Main Content

InflaRx announces successful closing of its round B financing

  • 2014

InflaRx announced today the suc­cess­ful clos­ing of its round B financ­ing by com­plet­ing the sec­ond of two tranches within this round. All cur­rent investors as well as new pri­vate investors par­tic­i­pated in this financ­ing round B reach­ing an invest­ment vol­ume in the dou­ble digit mil­lion Euro space. The pro­ceeds of this round will enable clin­i­cal phase II devel­op­ment of IFX‑1, the first-in-class anti com­ple­ment lead drug mon­o­clonal anti­body, in dif­fer­ent acute inflam­ma­tory indi­ca­tions. In addi­tion, the com­pany explained that this fund­ing shall fos­ter pre-clin­i­cal devel­op­ment of IFX‑2 as fol­low on anti­body for the treat­ment of selected chronic inflam­ma­tory dis­eases and enable the devel­op­ment of a new bed­side com­ple­ment acti­va­tion test in col­lab­o­ra­tion with a diag­nos­tic part­ner. Sup­ported by the lead invest­ment of the bm|t (beteili­gungs­man­age­ment thürin­gen gmbh) and other key stake­hold­ers, InflaRx man­aged to build a global net­work of pri­vate busi­ness investors. “We are very happy being able to close this round with com­mit­ted and excited investors espe­cially in the cur­rent finan­cial envi­ron­ment in Europe” says Prof. Niels Riede­mann, co-founder and CEO of the com­pany. “InflaRx offers a very excit­ing tech­nol­ogy and has been able to estab­lish a strong track record of deliv­er­ing its set mile­stones”, ads Udo Werner, CEO of bm|t.

The com­pany has recently been awarded the IQ Inno­va­tion Award in Ger­many for its anti-com­ple­ment tech­nol­ogy. InflaRx has started its first phase IIa trial with IFX‑1 in 2014 tar­get­ing infec­tious organ dys­func­tion in acutely site spe­cific sep­tic patients. In addi­tion the com­pany is set­ting up a sec­ond phase II trial pre­vent­ing sys­temic inflam­ma­tion and organ dys­func­tion in large scale surgery. Addi­tional clin­i­cal pro­grams are in the pipeline. “Dur­ing the past 6.5 years, we have focused on deliv­er­ing a first-in-class tech­nol­ogy tar­get­ing a key player of inflam­ma­tion and have now enlarged our tech­nol­ogy base to tar­get both, acute and chronic inflam­ma­tory dis­eases” explains Prof. Ren­feng Guo, co-founder and CSO of InflaRx. – “We believe that our tech­nol­ogy has the poten­tial to change clin­i­cal prac­tice in the field of inflam­ma­tion and to pro­vide ben­e­fit in areas of large med­ical need. This is what moti­vates and dri­ves our entire team”, ads Niels Riedemann.

Press contacts

InflaRx GmbH
Prof. Dr. Niels C. Riedemann

Winz­er­laer Strasse 2
D‑07745 Jena
Germany
+49–3641-508180
 www.inflarx.com
Back To Top
×Close search
Search